ストックスクリーナーアプリを入手
359.27
0.00%
0.010
アフターアワーズ：
359.00
-0.27
-0.08%
前日終値:
$359.26
開ける：
$362.29
24時間の取引高:
1.52M
Relative Volume:
1.16
時価総額：
$47.46B
収益：
$3.21B
当期純損益:
$43.57M
株価収益率:
1,493.85
EPS:
0.2405
ネットキャッシュフロー:
$221.36M
1週間 パフォーマンス:
-9.80%
1か月 パフォーマンス:
-8.16%
6か月 パフォーマンス:
+11.29%
1年 パフォーマンス:
+44.19%
1日の値動き範囲:
$355.46
$367.20
1週間の範囲:
$353.52
$378.61
52週間の値動き範囲:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
名前
Alnylam Pharmaceuticals Inc
セクター
電話
(617) 551-8200
住所
675 WEST KENDALL STREET, CAMBRIDGE, MA
ALNY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 再開されました | Oppenheimer | Outperform |
| 2025-08-04 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-08-04 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 再開されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2025-03-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-11-12 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-08-16 | アップグレード | Goldman | Neutral → Buy |
| 2024-02-16 | ダウングレード | Goldman | Buy → Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2023-10-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-05-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 開始されました | SMBC Nikko | Neutral |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Buy |
| 2022-09-09 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-06-07 | 開始されました | William Blair | Outperform |
| 2022-04-25 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 開始されました | Citigroup | Buy |
| 2022-02-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-01-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | アップグレード | Goldman | Neutral → Buy |
| 2021-11-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-10-04 | アップグレード | UBS | Neutral → Buy |
| 2021-08-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-02-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-02-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-01-25 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 再開されました | Berenberg | Hold |
| 2020-09-08 | 開始されました | Citigroup | Buy |
| 2020-08-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 再開されました | Evercore ISI | Outperform |
| 2020-03-19 | 開始されました | Berenberg | Buy |
| 2019-12-19 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-11-20 | 開始されました | Oppenheimer | Outperform |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-05-23 | 再開されました | Goldman | Neutral |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-03-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 開始されました | UBS | Neutral |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 繰り返されました | Stifel | Buy |
| 2018-08-07 | アップグレード | Stifel | Hold → Buy |
| 2018-05-04 | 繰り返されました | Stifel | Hold |
| 2018-03-28 | 開始されました | Evercore ISI | In-line |
すべてを表示
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
Price Action: What analysts say about Alnylam Pharmaceuticals Inc stockWeekly Investment Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
4 Next-Gen Candidates That Could Form the Future of Alzheimer’s Treatment - BioSpace
Aug Volume: How does Alnylam Pharmaceuticals Inc perform in inflationary periodsJuly 2025 Opening Moves & Stock Portfolio Risk Management - baoquankhu1.vn
Is It Time To Reassess Alnylam Pharmaceuticals (ALNY) After Recent RNAi Pipeline Progress? - simplywall.st
A Look Into Alnylam Pharmaceuticals Inc's Price Over Earnings - Benzinga
Insider Selling: Jeffrey V Poulton Unloads $1.01M Of Alnylam Pharmaceuticals Stock - Benzinga
How Does Geopolitics Affect the Life Sciences Industry? 3 Executives Weigh In - MedCity News
Alnylam EVP Pushkal Garg sells $547k in stock By Investing.com - Investing.com South Africa
Alnylam EVP Pushkal Garg sells $547k in stock - Investing.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $1,008,778.60 in Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) CEO Yvonne Greenstreet Sells 9,577 Shares - MarketBeat
Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells 1,510 Shares of Stock - MarketBeat
Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells 2,290 Shares of Stock - MarketBeat
JPM preannouncements: Why Alnylam and Sarepta lost, but Day One won - MSN
Is It Time To Reassess Alnylam (ALNY) After Recent Share Price Pullback? - Yahoo Finance
JPM26: 2025 a “breakout year” for rare disease biotechs - Yahoo Finance
Aug Gainers: What is ORLYs book value per shareQuarterly Profit Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Unveiling Its Alnylam 2030 Growth Plan - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Is Down 9.0% After Ambitious 2026 Guidance And 2030 Plan Reveal - Yahoo Finance
Market Review: What dividend safety score for Alnylam Pharmaceuticals Inc stockIndex Update & Reliable Intraday Trade Alerts - moha.gov.vn
H.C. Wainwright reiterates Buy rating on Alnylam stock with $570 price target - Investing.com UK
Tokio Marine Asset Management Co. Ltd. Takes $2.03 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Sumitomo Mitsui Trust Group Inc. Grows Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals CEO on Development Goals, Profitability - marketscreener.com
Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY - TechStock²
JPM preannouncements take their toll as Alnylam slides, Tempus, Day One pop - MSN
Lobbying Update: $70,000 of ALNYLAM PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance - BioWorld MedTech
Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short - TechStock²
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Gap Down After Analyst Downgrade - MarketBeat
Alnylam Pharmaceuticals Unveils “Alnylam 2030” as Amvuttra Drives Breakout Growth at JPMorgan Conf. - MarketBeat
JPM Kicks Off With Alnylam In the Red; But Others Surge - Investor's Business Daily
What's Going On With Alnylam Pharma Stock Monday?Alnylam Pharmaceuticals (NASDAQ:ALNY) - Benzinga
Alnylam (ALNY) Projects Strong Revenue Growth for 2026 Amidst TT - GuruFocus
AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations - BioPharma Dive
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Cut to $529.00 by Analysts at Bank of America - MarketBeat
B of A Securities Lowers Price Target for ALNY While Maintaining Buy Rating | ALNY Stock News - GuruFocus
Needham raises Alnylam Pharmaceuticals stock price target on strong 2026 guidance - Investing.com UK
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $529.00 - MarketBeat
Alnylam Pharmaceuticals (ALNY) Receives Rating Reaffirmation and Price Target Increase | ALNY Stock News - GuruFocus
Alnylam stock price target lowered to $529 by BofA on Q4 revenue miss - Investing.com UK
Nisa Investment Advisors LLC Has $5.53 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Raymond James reiterates Outperform rating on Alnylam stock at $472 target - Investing.com UK
Alnylam Pharmaceuticals stock rises as Goldman Sachs reiterates Buy rating By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: Unveiling a 22.96% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Alnylam Unveils 'Alnylam 2030' Strategy To Drive Growth And Innovation - Nasdaq
Los Angeles Daily NewsAlnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact - FinancialContent
Alnylam Launches “ Alnylam 2030 ” Strategy to Drive Next Era of Growth and Patient Impact - Business Wire
Will Alnylam’s New Five‑Year Roadmap and Early 2025 Revenue Update Redefine Its GARP Story (ALNY)? - simplywall.st
Is Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) 19% ROE Better Than Average? - Yahoo Finance
Alnylam raises 2025 revenue guidance to $3.05B amid robust AMVUTTRA ATTR-CM launch momentum - MSN
Alnylam Pharmaceuticals Inc (ALNY) 財務データ
収益
当期純利益
現金流量
EPS
1.63%
1.35%
大文字化:
|
ボリューム (24 時間):